Novo says diabetes drug IDegLira shows superior blood sugar control

COPENHAGEN Mon Dec 2, 2013 6:45pm EST

COPENHAGEN Dec 3 (Reuters) - Denmark's Novo Nordisk said on Tuesday that a phase 3 trial of its diabetes drug IDegLira showed better control of blood sugar levels than its own long-acting insulin Tresiba.

IDegLira is a combination of Tresiba and Victoza, Novo's glucagon-like peptide-1 (GLP-1) diabetes drug. GLP-1 drugs work by stimulating the release of insulin when blood sugar levels become too low.

Novo, the world's biggest insulin producer, said in a separate press release that its combination diabetes drug Ryzodeg showed improved glycaemic control, with lower rates of hypoglycaemia than biphasic insulin aspart 30.

Sales of diabetes drugs were worth $42.4 billion worldwide in 2012, according to healthcare information company IMS Health. France's Sanofi and U.S. company Eli Lilly are Novo's main competitors in the market.

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.